New ALS drug trial aims to slow disease and improve survival
NCT ID NCT06513546
First seen Feb 28, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tests a new drug called PLL001 in 153 adults with ALS (Lou Gehrig's disease). The goal is to see if it is safe and can slow the disease, improve daily function, and extend survival. Participants will receive daily injections of PLL001 or a placebo for up to 48 weeks, with an option to continue the drug in an open-label extension.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.